CD274 and cancer: The synergistic effects of anti-CTLA—direct enhancement of effector T cell function as well as inhibition of immunosuppressive Tregand indirect higher probability of DC maturation during the priming phase34, 174, 176— in conjunction with anti-PD-1/PD-L1 blockade in the immune effector phase have been verified as a therapeutic option in various advanced cancers including melanoma, colon, and lung cancer.177, 178, 179, 180